Study of XL999 in Patients With Acute Myeloid Leukemia (AML)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lynne Bui, MD
Exelixis
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Eddie Hu
Alhambra, California, United States
- Ronald Paquette
Los Angeles, California, United States
- the Thomas and Dorothy Leavey Cancer Center
Northridge, California, United States
- David Chan
Redondo Beach, California, United States
- Northwestern University Feinberg School of Medicine, Division of Hematology/oncology
Chicago, Illinois, United States
- American Health Network of Indiana
Indianapolis, Indiana, United States
- Section of Hematology/oncology Indiana Cancer Pavilion
Indianapolis, Indiana, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2006
- Primary completion
- 30 Nov 2006
- Completion
- 31 May 2007
- Last update posted
- 22 Feb 2010
- Registered enrollment
- 14
- Registry id
- NCT00322673
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.